JPH09509135A - 免疫寛容の誘導における利用のためのクリプティックペプチド - Google Patents

免疫寛容の誘導における利用のためのクリプティックペプチド

Info

Publication number: JPH09509135A
Authority: JP; Japan
Prior art keywords: peptide; composition; protein; allergen; antigen
Prior art date: 1993-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP7500034A

Other languages

English (en)

Japanese (ja)

Inventor

ロバートトマス，ウェイン

Original Assignee

ティーヴィダブリューテレソンインスティテュートフォーチャイルドヘルスリサーチ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-02

Filing date

1994-06-01

Publication date

1997-09-16

1994-06-01 Application filed by ティーヴィダブリューテレソンインスティテュートフォーチャイルドヘルスリサーチ filed Critical ティーヴィダブリューテレソンインスティテュートフォーチャイルドヘルスリサーチ

1997-09-16 Publication of JPH09509135A publication Critical patent/JPH09509135A/ja

Status Pending legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 189
230000001939 inductive effect Effects 0.000 title claims abstract description 10
230000006058 immune tolerance Effects 0.000 title claims description 7
102000004196 processed proteins & peptides Human genes 0.000 title abstract description 66
108091007433 antigens Proteins 0.000 claims abstract description 81
102000036639 antigens Human genes 0.000 claims abstract description 81
239000013566 allergen Substances 0.000 claims abstract description 46
238000000034 method Methods 0.000 claims abstract description 46
239000000203 mixture Substances 0.000 claims abstract description 44
239000000427 antigen Substances 0.000 claims abstract description 32
241000282414 Homo sapiens Species 0.000 claims abstract description 11
239000003937 drug carrier Substances 0.000 claims abstract description 7
230000001900 immune effect Effects 0.000 claims abstract description 6
210000004027 cell Anatomy 0.000 claims description 41
108090000623 proteins and genes Proteins 0.000 claims description 39
102000004169 proteins and genes Human genes 0.000 claims description 36
-1 rh factor Proteins 0.000 claims description 13
230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 claims description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
241000238740 Dermatophagoides pteronyssinus Species 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 5
210000001685 thyroid gland Anatomy 0.000 claims description 5
241000219495 Betulaceae Species 0.000 claims description 4
241000238658 Blattella Species 0.000 claims description 4
108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 claims description 4
241000209082 Lolium Species 0.000 claims description 4
241000238661 Periplaneta Species 0.000 claims description 4
241000219492 Quercus Species 0.000 claims description 4
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 3
108010009685 Cholinergic Receptors Proteins 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
102000018697 Membrane Proteins Human genes 0.000 claims description 3
108010052285 Membrane Proteins Proteins 0.000 claims description 3
102000047918 Myelin Basic Human genes 0.000 claims description 3
101710107068 Myelin basic protein Proteins 0.000 claims description 3
102000034337 acetylcholine receptors Human genes 0.000 claims description 3
210000002469 basement membrane Anatomy 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 3
102000005962 receptors Human genes 0.000 claims description 3
241000223600 Alternaria Species 0.000 claims 3
241000256836 Apis Species 0.000 claims 3
241000219429 Betula Species 0.000 claims 3
235000003932 Betula Nutrition 0.000 claims 3
241000282465 Canis Species 0.000 claims 3
241000218692 Cryptomeria Species 0.000 claims 3
241000238710 Dermatophagoides Species 0.000 claims 3
241001127637 Plantago Species 0.000 claims 3
240000006694 Stellaria media Species 0.000 claims 3
102100032378 Carboxypeptidase E Human genes 0.000 claims 2
108010058255 Carboxypeptidase H Proteins 0.000 claims 2
102000008214 Glutamate decarboxylase Human genes 0.000 claims 2
108091022930 Glutamate decarboxylase Proteins 0.000 claims 2
210000001744 T-lymphocyte Anatomy 0.000 description 75
230000004044 response Effects 0.000 description 40
235000018102 proteins Nutrition 0.000 description 31
241000699670 Mus sp. Species 0.000 description 28
125000000539 amino acid group Chemical group 0.000 description 28
238000000338 in vitro Methods 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
239000002609 medium Substances 0.000 description 14
230000004927 fusion Effects 0.000 description 12
239000002253 acid Substances 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 11
239000000126 substance Substances 0.000 description 10
238000011282 treatment Methods 0.000 description 10
108010002350 Interleukin-2 Proteins 0.000 description 9
102000000588 Interleukin-2 Human genes 0.000 description 9
210000001165 lymph node Anatomy 0.000 description 9
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 8
125000003275 alpha amino acid group Chemical group 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
210000004698 lymphocyte Anatomy 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
239000008001 CAPS buffer Substances 0.000 description 7
108010002386 Interleukin-3 Proteins 0.000 description 7
230000005867 T cell response Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
206010020751 Hypersensitivity Diseases 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
108010058846 Ovalbumin Proteins 0.000 description 6
102000007079 Peptide Fragments Human genes 0.000 description 6
108010033276 Peptide Fragments Proteins 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
208000026935 allergic disease Diseases 0.000 description 6
230000007815 allergy Effects 0.000 description 6
230000027455 binding Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000012634 fragment Substances 0.000 description 6
230000028993 immune response Effects 0.000 description 6
230000006698 induction Effects 0.000 description 6
229940092253 ovalbumin Drugs 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
238000003556 assay Methods 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000012894 fetal calf serum Substances 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000006052 T cell proliferation Effects 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000012258 culturing Methods 0.000 description 4
230000036039 immunity Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000012360 testing method Methods 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108090000978 Interleukin-4 Proteins 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
230000000172 allergic effect Effects 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
238000001516 cell proliferation assay Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
239000003365 glass fiber Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000004073 interleukin-2 production Effects 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012546 transfer Methods 0.000 description 3
229910052722 tritium Inorganic materials 0.000 description 3
239000013598 vector Substances 0.000 description 3
206010003645 Atopy Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000023328 Basedow disease Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
208000015023 Graves' disease Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
230000017274 T cell anergy Effects 0.000 description 2
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000001994 activation Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
239000000428 dust Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
230000001175 peptic effect Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
244000036975 Ambrosia artemisiifolia Species 0.000 description 1
235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
102000006306 Antigen Receptors Human genes 0.000 description 1
108010083359 Antigen Receptors Proteins 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
241001070941 Castanea Species 0.000 description 1
235000014036 Castanea Nutrition 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
240000005109 Cryptomeria japonica Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001024304 Mino Species 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010071384 Peptide T Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710118538 Protease Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
241000251221 Triakidae Species 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
230000000981 bystander Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000005859 cell recognition Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
210000000991 chicken egg Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
239000000539 dimer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
208000001031 fetal erythroblastosis Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000036541 health Effects 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
229940124736 hepatitis-B vaccine Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006069 physical mixture Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940070376 protein Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
102000004217 thyroid hormone receptors Human genes 0.000 description 1
108090000721 thyroid hormone receptors Proteins 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP7500034A 1993-06-02 1994-06-01 免疫寛容の誘導における利用のためのクリプティックペプチド Pending JPH09509135A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US7283293A	1993-06-02	1993-06-02
US08/072,832		1993-06-02
PCT/AU1994/000292 WO1994027634A1 (en)	1993-06-02	1994-06-01	Cryptic peptides for use in inducing immunologic tolerance

Publications (1)

Publication Number	Publication Date
JPH09509135A true JPH09509135A (ja)	1997-09-16

Family

ID=22110024

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP7500034A Pending JPH09509135A (ja)	1993-06-02	1994-06-01	免疫寛容の誘導における利用のためのクリプティックペプチド

Country Status (6)

Country	Link
EP (1)	EP0705108A4 (de)
JP (1)	JPH09509135A (de)
AU (1)	AU674584B2 (de)
CA (1)	CA2164326A1 (de)
NZ (1)	NZ266739A (de)
WO (1)	WO1994027634A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0783322A1 (de) *	1994-09-02	1997-07-16	Immunologic Pharmaceutical Corporation	Peptidzusammensetzungen mit der fähigkeitantigenspezifische immunantworten herunterregulieren zu können
US6759234B1 (en)	1994-09-02	2004-07-06	Immulogic Pharmaceutical Corporation	Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
CA2232834A1 (en) *	1995-09-21	1997-03-27	University Of Utah	Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells
JPH09194393A (ja)	1996-01-22	1997-07-29	Meiji Milk Prod Co Ltd	免疫寛容を誘導する方法、免疫寛容誘導食品キットおよび免疫寛容誘導剤キット
US6737406B1 (en)	1996-03-21	2004-05-18	Circassia, Ltd.	Cryptic peptides and method for their identification
US7097845B2 (en)	1997-04-23	2006-08-29	Jacob Sten Petersen	Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US6024961A (en) *	1997-11-14	2000-02-15	Washington University	Recombinant avirulent immunogenic S typhi having rpos positive phenotype
US6455686B1 (en) *	1998-04-17	2002-09-24	Heska Corporation	Dermatophagoides nucleic acid molecules, proteins and uses thereof
US7128921B1 (en)	1998-04-17	2006-10-31	Heska Corporation	Dermatophagoides proteins and fragments thereof
FR2822709B1 (fr) *	2001-03-30	2007-01-19	Antialis	Composition pharmaceutique anti-allergique comprenant au moins un allergene et au moins un compose antihistaminique
CA2554337A1 (en)	2004-02-06	2005-08-25	Greer Laboratories, Inc.	Methods and compositions for dosing of allergens
GB0710529D0 (en)	2007-06-01	2007-07-11	Circassia Ltd	Vaccine
NZ583362A (en)	2007-08-15	2012-06-29	Circassia Ltd	Peptide with reduced dimer formation
CN110064049B (zh)	2012-06-21	2024-02-09	西北大学	肽缀合粒子
KR20160042079A (ko)	2013-08-13	2016-04-18	노쓰웨스턴유니버시티	펩티드-접합된 입자
JP7194593B2 (ja)	2015-12-23	2022-12-22	クールファーマシューティカルズディベロップメントカンパニーインコーポレイテッド	共有ポリマー抗原コンジュゲート化粒子
WO2025199149A1 (en)	2024-03-18	2025-09-25	Cour Pharmaceuticals Development Company Inc.	Sting agonism for antigen specific tolerance

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2993967B2 (ja) *	1987-06-17	1999-12-27	インスティテュート・フォー・チャイルド・ヘルス・リサーチ	ダニアレルゲンのクローニング
EP0359783B2 (de) *	1987-06-24	2002-04-17	Autoimmune, Inc.	Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
CA2070281C (en) *	1989-12-20	2005-08-23	David Allen Hafler	Improved treatment of autoimmune diseases by aerosol administration of auto antigens
AU651097B2 (en) *	1990-03-02	1994-07-14	Autoimmune, Inc.	Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
EP0503055A1 (de) *	1990-09-06	1992-09-16	Rijksuniversiteit Utrecht	Inhibitor der lymphozyten-antwort und immunverwandter krankheiten
WO1992004632A1 (en) *	1990-09-07	1992-03-19	The Regents Of The University Of California	Methods for the diagnosis and treatment of diabetes
HUT69942A (en) *	1990-10-15	1995-09-28	Brigham & Womens Hospital	Treatment of autoimmun diseases by oral administration of autoantigenes
DE69233772D1 (de) *	1991-10-16	2009-11-12	Merck Patent Gmbh	T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
HU220357B (hu) *	1992-02-28	2001-12-28	Autoimmune Inc.	Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
IL105153A (en) *	1992-03-25	1999-12-22	Immulogic Pharma Corp	Therapeutic compositions comprising peptides derived from human t cell reactive feline protein

1994
- 1994-06-01 EP EP94916845A patent/EP0705108A4/de not_active Withdrawn
- 1994-06-01 WO PCT/AU1994/000292 patent/WO1994027634A1/en not_active Ceased
- 1994-06-01 JP JP7500034A patent/JPH09509135A/ja active Pending
- 1994-06-01 NZ NZ266739A patent/NZ266739A/en unknown
- 1994-06-01 CA CA002164326A patent/CA2164326A1/en not_active Abandoned
- 1994-06-01 AU AU68385/94A patent/AU674584B2/en not_active Ceased

Also Published As

Publication number	Publication date
EP0705108A1 (de)	1996-04-10
EP0705108A4 (de)	1997-08-06
CA2164326A1 (en)	1994-12-08
WO1994027634A1 (en)	1994-12-08
NZ266739A (en)	1997-07-27
AU674584B2 (en)	1997-01-02
AU6838594A (en)	1994-12-20

Publication	Publication Date	Title
US20240058442A1 (en)	2024-02-22	Combinations of Modalities for the Treatment of Diabetes
JPH09509135A (ja)	1997-09-16	免疫寛容の誘導における利用のためのクリプティックペプチド
EP0871486B1 (de)	2005-01-26	Epitope von diphtheriatoxin
US6759234B1 (en)	2004-07-06	Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
US6884785B2 (en)	2005-04-26	Compositions and methods for the treatment or prevention of autoimmune diabetes
JP2607751B2 (ja)	1997-05-07	自己免疫性ブドウ膜網膜炎の治療予防薬
JPH08500083A (ja)	1996-01-09	ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
RU2598247C2 (ru)	2016-09-20	Изменение иммуногенности антигена путем устранения эпитопов, узнаваемых nkt-клетками
EP2989121B1 (de)	2020-10-07	Verfahren zur herstellung und zusammensetzung von peptidkonstrukten für die behandlung von rheumatoider arthritis
JP2001517208A (ja)	2001-10-02	損傷した細胞ペプチドプロセッシングに関連する、例えばｂ７−１遺伝子で形質転換したｒｍａ−ｓ細胞上に発現される抗原またはエピトープの治療的応用
US20040138116A1 (en)	2004-07-15	Tolerogenic approach for type 1 diabetes
JPH10505356A (ja)	1998-05-26	ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド
US20160158330A1 (en)	2016-06-09	Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
JP7778696B2 (ja)	2025-12-02	Ｓ－アレスチンペプチドを含む組成物
AU748104B2 (en)	2002-05-30	Peptide compositions capable of down regulating an antigen specific immune response
HUT77806A (hu)	1998-08-28	Antigénspecifikus immunválaszt alulszabályozó peptidkészítmények
AU2005202898A1 (en)	2005-08-11	Compositions and methods for the treatment or prevention of autoimmune disorders
BG63183B2 (bg)	2001-05-31	Анти-идиотипна ваксина срещу заболявания в резултат от патогенни отговори на специфични т-клетъчни популации